	US 11,897,966 B2
	Mesothelin-targetting antibodies, chimeric antigen receptors, and uses thereof
Yangbing Zhao, Shanghai (CN); Gengzhen Zhu, Shanghai (CN); and Xiaojun Liu, Shanghai (CN)
Assigned to UTC THERAPEUTICS (SHANGHAI) CO., LTD., Shanghai (CN)
Filed by UTC THERAPEUTICS (SHANGHAI) CO., LTD., Shanghai (CN)
Filed on Dec. 6, 2022, as Appl. No. 18/062,084.
Application 18/062,084 is a continuation of application No. PCT/CN2022/112726, filed on Aug. 16, 2022.
Claims priority of application No. PCT/CN2021/112855 (WO), filed on Aug. 16, 2021.
Prior Publication US 2023/0235081 A1, Jul. 27, 2023
Int. Cl. C07K 16/30 (2006.01); C07K 14/725 (2006.01); C07K 14/705 (2006.01)

CPC C07K 16/30 (2013.01) [C07K 14/7051 (2013.01); C07K 14/70517 (2013.01); C07K 14/70578 (2013.01); C07K 2317/622 (2013.01); C07K 2319/02 (2013.01); C07K 2319/03 (2013.01)]

28 Claims

1. An antibody or antigen-binding fragment thereof that specifically binds mesothelin and comprises a VL CDR1, a VL CDR2, a VL CDR3, a VH CDR1, a VH CDR2 and a VH CDR3, wherein

(a) the VL CDR1, CDR2 and CDR3 have the amino acid sequences of SEQ ID NOs: 1, 2, and 3 respectively; and

(b) the VH CDR1, CDR2 and CDR3 have the amino acid sequences of SEQ ID NOs: 4, 5, and 6 respectively.